Kornimate/medical-research-clean huggingface dataset:
impact of cervical parameters to interlaminar epidural steroid injection treatment outcomes in patients with cervical disc herniation

Conditions: Cervical Disc Herniation

Summary: this study is aim to disclose the effect of cervical parameters, whether they change the outcomes of epidural steroid injection treatment in patients with cervical disc herniation. the patients who had cervical disc herniation and had been performed interlaminar epidural steroid injection were included. we hypothesized that participants with abnormal cervical spine alignment parameters were less likely to benefit from treatment.

the objective of this study is to reveal the impact of cervical sagittal parameters on interlaminar epidural steroid injections in patients with cervical disc herniation. patients who have suffered from cervical radicular pain for at least 3 months and been diagnosed with cervical radiculopathy in our pain clinic in the subsequent stage, with a clinical and physical examination, as well as radiologic assessments, were included in the study. other inclusion criteria were intractable pain over the neck despite conservative treatment and being between the ages of 18 and 65. patients with a history of epidural steroid injections carried out in the previous 3 months, patients with a history of cervical spine surgery, patients with systemic and/or local infections, malignancy, bleeding diathesis, acute fracture, known allergy to contrast material and/or local anesthetic substances, known history of any psychiatric disorder, and patients with a history of pregnancy were excluded from the study. verbal and written informed consent was obtained from all patients participating in the study. in addition to the recording of the demographic data of the patients participating in this study (age, sex, duration of symptoms, etc.), their sagittal parameters angles (c2-c7 cervical lordosis, c2-c7 sagittal vertical axis, c7 slope and spino-cranial angle) and the numeric rating scale (nrs) was employed before the procedure and in the 1st hour, 3rd week, and 3rd month after the procedure. short form-12 health survey (sf-12) was employed before the procedure and in the 3rd week and 3rd month after the procedure.

Eligibility criteria:
inclusion criteria: * patients who have suffered from neck pain for at least 3 months and been diagnosed with cervical radiculopathy * intractable pain despite conservative treatment and being between the ages of 18 and 65 * patients who will be performing with an interlaminar epidural steroid injection(ilesi) exclusion criteria: * patients with a history of ilesi carried out in the previous 3 months, * patients with a history of cervical surgery, * patients with systemic and/or local infections, * malignancy, * bleeding diathesis, * acute fracture, * known allergy to contrast material and/or local anesthetic substances, * known history of any psychiatric disorder * patients with a history of pregnancy

Keywords: cervical sagittal parameters
evaluation of myocardial viability : dual energy cardiac ct vs. cardiac mri

Conditions: Myocardial Infarction

Summary: the purpose of this study is therefore to show that associated with cardiac angiography echocardiography, in myocardial seen late, would provide the information necessary for the decision revascularization, in a timely manner. this would allow the patient to avoid duplication of tests including risk related to coronary angiography (bleeding complications, stroke ...) and those related to the implantation of coronary stent (stent) without expected earnings in case of non-viability . this would also reduce the length of hospital stay and costs due to numerous reviews.

percutaneous coronary intervention is not recommended in stable patients with late presentation myocardial infarction, and myocardial viability needs to be evaluated before the procedure. the aim of the study is to evaluate the sensibility and specificity of dual-energy ct for the evaluation of myocardial viability in comparison to cardiac mri. the experimental procedure is limited to a second ct acquisition performed 10 minutes in dual energy mode. sensitivity and specificity of delayed enhancement \>50% of myocardial thickness provided by dual-energy ct will be evaluated in comparison to cardiac mri.

Eligibility criteria:
inclusion criteria: * man or woman * major patient * patient with electrical, biological and clinical signs of myocardial infarction, with late presentation (\>24 hours) * creatinine clearance (calculated using the cockcroft (\ 65 years))formula \> 30 ml / min. * affiliation to the french social security scheme. * women of childbearing age: negative pregnancy test (urine test). * postmenopausal women, menopause confirmation of diagnosis * patient able to understand the spoken and written french. * signature of informed consent exclusion criteria: * collapsus or organ failure requiring urgent care in intensive care unit * arrhythmia and/or non-reducible tachycardia. * history of allergic reaction after iodinated contrast medium injection. * history of nephrogenic systemic fibrosis. * history of claustrophobia * unbalanced asthma. * acute pulmonary edema. * pregnant or breastfeeding women. * clinical signs of thyrotoxicosis. * person placed under judicial protection, * patient suffering from serious psychiatric disease. * patients participating in another clinical trial. * contraindication to mri

Keywords: cardiac angiography cardiac mri
pde-4 inhibitor roflumilast and glp-1 agonist liraglutide in polycystic ovary syndrome

Conditions: PCOS; Obesity

Summary: the purpose of this study was to determine whether monotherapy treatment with phosphodiesterase-4 (pde-4) inhibitor roflumilast is more effective than treatment with glucagon-like protein 1 (glp-1) liraglutide or treatment with metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome (pcos) regarding weight reduction who have not been treated before. the investigators anticipated greater changes in body weight in patients on roflumilast treatment than in liraglutide or metformin.


Eligibility criteria:
inclusion criteria: * 18 years old to menopause * polycystic ovary syndrome (nichd criteria) * bmi of 30 kg/m² or higher exclusion criteria: * depression * type 1 or type 2 diabetes mellitus * history of carcinoma * history of pancreatitis * cushing's syndrome or congenital (non-classic) adrenal hyperplasia * significant cardiovascular, kidney or hepatic disease * the use of medications other than metformin known or suspected to affect reproductive or metabolic functions * the use of statins, within 90 days prior to study entry

Keywords: pcos pde-4 inhibitor roflumilast liraglutide metformin obesity
biomarkers of acute kidney injury in cardiac surgery

Conditions: Acute Kidney Injury (Nontraumatic)

Summary: acute kidney injury (aki) is the most common complication in patients after cardiac surgery. an usual estimation of risk for aki is estimation of serum creatinine, which is unreliable indicator of aki risk. because of that, today different biomarkers are investigated to predict incidence for development aki after cardiac surgery. this investigation will try to find potentially risk patients for developing aki after cardiac surgery by using conventional markers (creatinine, glomerular filtration rate) in perioperative period comparing with two different biomarkers neutrophil gelatinase-associated lipocalin (ngal) and growth differentiation factor 15 (gdf-15) which are proven markers in patients with increased risk for aki development.


Eligibility criteria:
inclusion criteria: * patients scheduled for cardiac surgery (cabg, valve replacement/repair, combined) * older than 18 years exclusion criteria: * previous known renal disease * patients on chronic dialysis

Keywords: acute kidney injury cardiac surgery ngal gdf-15
adhesion of lidocaine topical system 1.8%

Conditions: Healthy

Summary: the objective of this study is to evaluate the adhesion performance of ztlido (lidocaine topical system) 1.8% in normal, healthy volunteers.

in this open-label, single-treatment, single-period, single-application adhesion performance study, 54 healthy, adult male and female subjects are treated with one lidocaine topical system to their back for 12 hours. adhesion will be monitored throughout the wear time and skin irritation will be assessed after the topical system is removed.

Eligibility criteria:
key inclusion criteria: * must be healthy based on by medical history, laboratory work, and physical exam * be at least 18 years of age * if childbearing potential, use of acceptable form of birth control * in the case of females of childbearing potential, have a negative serum pregnancy test key exclusion criteria: * allergy or known hypersensitivity to lidocaine, amide-type local anesthetics, or any component of the product formulation * any major medical illness 3 months prior or any significant history or ongoing chronic medical illness * subjects with conditions that might affect application of the product or its adhesive properties (including psoriasis, eczema, atopic dermatitis, damaged or irritated epidermal layer, and excessive hair or oil on the skin) * history of addiction, abuse, and misuse of any drug
neurophenotype predicts cd disease progression

Conditions: Radiomics; Multi-omics

Summary: the goal of this observational study is aimed to develop a novel multimodal neuroimaging-based model to characterize the neurophenotype of crohn's disease patients and assess its ability for predicting disease progression, using multiomics data to interpret the model. participants will be followed-up of at least six months for patients without disease progression to assess the relationship between neurophenotype and intestinal outcomes.

brain-gut axis plays a crucial role in the pathogenesis of crohn's disease (cd); however, cd neurophenotype and its impact on intestinal disease progression remain unclear. we aimed to develop a novel multimodal neuroimaging-based model to characterize the neurophenotype of cd patients and assess its ability for predicting disease progression, using multiomics data to interpret the model. this study enrolled cd patients who underwent baseline testing (including neuroimaging, psychological scales, mr enterography, and ileocolonoscopy) and faecal/blood samples collection. the neurophenotypes of patients were characterized using a neuroimaging-based model. the predictive ability of neurophenotype model for disease progression was evaluated using cox regression analysis. multiomics data (including faecal microbiome, faecal/blood metabolomics, intestinal permeability, blood-brain-barrier permeability, and blood neurotransmitter levels) were used to elucidate how neurophenotypes reflect brain-gut interactions.

Eligibility criteria:
inclusion criteria: * (a) cd patients aged 18-45 years; (b) the completion of multimodal brain mri and administration of psychological questionnaires; (c) mr enterography (mre), ileocolonoscopy, and blood or faecal samples, collection within one week of brain mri; (d) a follow-up of at least six months for patients without disease progression; and (e) right-handedness. exclusion criteria: * (a) recent use of antibiotics, probiotics, or prebiotics within three months prior to inclusion; (b) history of neurosurgery, cerebrovascular disease, or brain trauma; (c) use of central nervous system drugs or antidepressants within three months prior to inclusion; (d) identification of brain lesions on mr scan; (e) claustrophobia; or (f) presence of metal implants.

Keywords: abdominal mri magnetic resonance imaging crohn's disease brain/gut interaction
a study of 2 doses of a hepatitis b vaccine (v232 recombivax hb) in healthy infants (v232-057)

Conditions: Hepatitis B

Summary: this study was conducted in healthy infants and will provide new immunogenicity and safety data for the modified process hepatitis b vaccine. this study was conducted to address the following: to evaluate the immunogenicity and safety data of the 5 microgram dose of the modified process hepatitis b vaccine compared with a 10 microgram dose of the modified process hepatitis b vaccine, to evaluate another dosing schedule of 2, 4, and 6 months, and to provide descriptive immunogenicity data of another marketed vaccine (engerix-b®).


Eligibility criteria:
inclusion criteria: * participant is a healthy infant approximately 2 months of age exclusion criteria: * birth mother is a known carrier of hepatitis b virus or another known carrier has lived in close contact with the participant * participant's birth mother did not receive any prenatal care * participant has previous history of hepatitis b infection * participant has been vaccinated against hepatitis b or birth mother was vaccinated within 6 months before birth of participant * participant has had a fever within 72 hours of study start * participant has received any blood-derived product or birth mother received blood-derived product within 6 months of birth of participant
clinical efficacy of 810 nanometer diode laser as an adjunct to mechanical periodontal treatment of residual periodontal pockets

Conditions: Chronic Periodontitis

Summary: background: aim of this randomized controlled parallel-designed study was to evaluate the effects of diode laser as an adjunct to mechanical periodontal treatment on clinical parameters and gingival crevicular fluid (gcf) volume of the residual pockets diagnosed following initial periodontal treatment in chronic periodontitis (cp) patients. methods: a total of 84 residual pockets on single-rooted teeth in 11 cp patients were included and randomly assigned into 3 groups. residual pockets were treated either only by mechanical treatment (group m) (n=28), only by diode laser disinfection (group l) (n=28) or by combination of these techniques (group m+l) (n=28). plaque index, gingival index (gi), bleeding on probing (bop), probing depth (pd), clinical attachment level and gingival recession were assessed at baseline and 8 weeks after treatment of residual pockets. gcf samples were collected at baseline, 1 and 8 weeks after treatment.


Eligibility criteria:
inclusion criteria: * systemically healthy, * non-smoker, * chronic periodontitis diagnosed according to armitage 1, * aged between 35 and 65, * not received any periodontal treatment within the last 3 months, * have horizontal bone loss radiographically, * presence at least 20 natural teeth except third molars * consent to participate in the study. exclusion criteria: * any systemic disease that might interfere with the prognosis of periodontal disease (i.e. diabetes mellitus, hiv infection), * smoking, * antibiotics, anti-inflammatory drugs or any other medication taken within the previous 6 months that may affect the outcome of the study, * any physical limitations or restrictions that might preclude normal oral hygiene procedures.

Keywords: chronic periodontitis dental scaling gingival crevicular fluid lasers periodontal pocket root planing
game-based digital intervention for relieving depression and anxiety symptoms

Conditions: Depression; Anxiety

Summary: objective: to collect preliminary data and assess the preliminary effectiveness of a game-based digital therapeutics (dtx) intervention for individuals with symptoms of anxiety and depression, and to investigate whether reinforcement learning (rl) can personalize the intervention and enhance effectiveness. design: randomized controlled trial with three arms. setting: internet-based recruitment and delivery of the intervention. participants: 223 individuals with symptoms of anxiety and depression, aged between 18 and 50 years. interventions: participants were randomly assigned to one of three groups: game-based dtx with rl algorithm (rl algorithm group), game-based dtx without rl algorithm (no algorithm group), and a blank control group. main outcomes and measures: the primary outcomes were reductions in symptoms of anxiety and depression, measured using the patient health questionnaire-9 and generalized anxiety disorder 7-item scales. response rates and rates of recovery, as well as the impact of demographic variables, were also examined.


Eligibility criteria:
inclusion criteria: 1. age between 18 and 60 years; 2. having a phq-9 score or a gad-7 score upon enrollment; 3. being able to operate a smartphone fluently; 4. having normal vision after correction exclusion criteria: 1. clinical diagnoses of severe psychiatric conditions such as schizophrenia or bipolar disorder; 2. at high risk of suicide or self-harm; 3. having significant cognitive impairments; 4. active substance abuse or dependence; 5. currently undergoing other psychological or pharmacological treatments for depression or anxiety; 6. pregnant individuals or those with postpartum depression, and those with serious physical health conditions that could impact mental health.
non-interventional study of novoseven® used in patients with haemophilia a and b with inhibitors under normal clinical practice

Conditions: Congenital Bleeding Disorder; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors

Summary: this study is conducted in japan. the aim of this non-interventional study is to investigate the safety and effectiveness of treatment with eptacog alpha (novoseven®) under normal clinical practice conditions.


Eligibility criteria:
inclusion criteria: * patients with haemophilia a and b with inhibitors who received eptacog alpha (novoseven®) as treatment exclusion criteria: * patients who was not deemed to be appropriate to the treatment of eptacog alpha (novoseven®)
effects of a food supplement in the prevention of urinary tract infections in kidney transplant patients.

Conditions: Kidney Transplant Infection

Summary: the incidence of urinary tract infections (utis) is very high in kidney transplant patients. most utis occur during the first six months (82% within the first three months) of kidney transplantation and are frequently recurrent. the component d-mannose of our authorized food supplement acts by inhibiting the adherence of e.coli to the urothelium. it also has a controlled release formula that ensures the presence in urine of d-mannose and the other components during 24 hours. this is the reason why this experimental study aims to demonstrate that the oral intake of this food supplement is effective in the prevention of utis in kidney transplant patients.

the study tries to analyze the impact of a food supplement (manosar®) on the incidence of urinary infections in patients undergoing kidney transplantation. the patients will be randomly distributed (1: 1 ratio) into two treatment groups of 30 patients each. in one group, they will be treated with manosar®, and in the other group they will be treated with proanthocyanidins. all patients will be followed for 6 months, being the first three months of the study drug administration. this experimental study is double-blinded and there are 7 monthly study visits. properties of d-mannose and proanthocyanidins make interesting to evaluate the clinical benefit of the use of food supplements with d-mannose and proanthocyanidins in order to prevent the utis without antibiotics.

Eligibility criteria:
inclusion criteria: * ≥ 18 years. * recipients of a cadaveric donor kidney transplant. * patients who are trained to give their informed consent. exclusion criteria: * recipients of a kidney transplant who do not authorize their participation in the study by informed consent. * recipients of a transplant of an organ other than the kidney. * patients with bricker or studer neobladders. * patients in need of intermittent self-catheterization prior to kidney transplantation. * any medical, psychiatric or family condition that, in the opinion of the investigator, may endanger or compromise the patient's ability to participate in the study. * pregnant or lactating patients. * having participated in clinical trials in the previous 3 months or participating in another clinical study promoted by the pharmaceutical industry, in which the promoter already establishes the treatment for uti.
pounds off digitally (pod): the use of podcasting and mobile media to promote weight loss

Conditions: Obesity; Overweight

Summary: overweight and obesity play a role in both cancer incidence and survival rates. many people have found attending weight loss support groups to be time-intensive. past research has shown electronic media, particularly the web, to be effective in producing weight loss. the web, however, lacks portability, which prevents people from accessing the information when it is convenient for them. providing weight loss information via podcasting (audio files that may be listened to on portable audio players) may allow people to receive weight loss tips anywhere. a previous research study showed that podcasts emphasizing healthy eating and exercise can help people lose weight. this study was short-term and did not include additional social support. the purpose of this research project is to assess the effectiveness of a weight loss intervention delivered through podcasts as compared to the same podcast with added mobile media such as self-monitoring software (such as a pedometer) and support delivered via a social networking site. for this research study, the investigators will conduct a 6-month study in 104 overweight adults to determine if a podcast plus mobile media support leads to greater weight loss than a podcast alone.


Eligibility criteria:
inclusion criteria: * be between the ages of 18-60 years old * be a non-smoker * live in the chapel hill, nc area * be able to attend monitoring visits at baseline, 3-months, and 6-months * have access to the internet and a computer * have access to an internet-capable mobile device (such as an iphone, ipod touch, or blackberry) and an mp3 player (this may be the same device) * have access to a scale for self-monitoring weight * be willing to be randomized to either group * be free of psychiatric diseases, drug or alcohol dependency, or uncontrolled thyroid conditions * be free of major health conditions, such as heart conditions, diabetes, and past incidence of stroke * have md consent for participation if currently on blood pressure medications, have issues with dizziness, or have bone or joint issues. * able to prepare all their own meals (i.e. not living on-campus) exclusion criteria: * should not be pregnant, anticipating on becoming pregnant in the next 7 months, or currently breastfeeding * be free of an eating disorder as screened by the eating disorder screen for primary care \[esp\]. * no current participation in a weight loss program or taking weight loss medications (although participants may be trying to lose weight on their own) * have not participated in previous podcasting weight loss research